News-Medical.Net

Unveiling ADC cellular internalization with pH-sensitive dye detection

Learn how pH-sensitive dye detection supports reliable ADC internalization assays and insight into cellular uptake mechanisms ...
Morningstar

Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical data showing its proprietary ...
Seeking Alpha

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer

BOSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today ...
Nasdaq

Akari Advances Towards First-in-Human Trial With Novel ADC Payload

(RTTNews) - Akari Therapeutics, Plc (Nasdaq: AKTX) yesterday announced that it has initiated GMP manufacturing of its lead antibody-drug conjugate (ADC), AKTX-101, marking a pivotal step toward its ...

Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors

Company expands its ADC pipeline and patent estate for novel, differentiated ADCsNew pipeline candidate AKTX-102 leverages ...
MarketWatch

Precision Biologics to Reveal Preclinical Efficacy of Novel Tumor-Specific ADC against multiple human cancer types at SITC 2025

The MarketWatch News Department was not involved in the creation of this content. BETHESDA, Md., Nov. 5, 2025 /PRNewswire/ -- Precision Biologics, Inc. announces in vitro and in vivo efficacy of its ...